20240043450. NEW COMPOUND simplified abstract (JANSSEN PHARMACEUTICA NV)
Contents
NEW COMPOUND
Organization Name
Inventor(s)
Nina Van Opdenbosch of Scheldewindeke (BE)
Michiel Luc Maria Van Gool of Madrid (ES)
Dries Van Rompaey of Schoten (BE)
Gary John Tresadern of Antwerpen (BE)
Josep Llaveria Cros of Madrid (ES)
Mohamed Lamkanfi of Beerse (BE)
NEW COMPOUND - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240043450 titled 'NEW COMPOUND
Simplified Explanation
The invention relates to novel compounds that can inhibit the production of NLRP3 inflammasome, which is associated with certain diseases or disorders. These compounds are defined by the formula (i) and the specific values of the integers r, r, and r as described in the patent application. The compounds have potential use as medicaments for the treatment of diseases or disorders associated with NLRP3 inflammasome activity.
- The invention is about novel compounds that can inhibit NLRP3 inflammasome production.
- The compounds are defined by a specific formula and integer values.
- The compounds may be used as medicaments for treating diseases or disorders associated with NLRP3 inflammasome activity.
Potential Applications
The technology has potential applications in the field of medicine and pharmaceuticals. It can be used for:
- Treatment of diseases or disorders associated with NLRP3 inflammasome activity.
- Development of new medications targeting NLRP3 inflammasome production.
Problems Solved
This technology addresses the following problems:
- Diseases or disorders associated with NLRP3 inflammasome activity.
- Limited treatment options for conditions related to NLRP3 inflammasome activity.
Benefits
The technology offers several benefits:
- Novel compounds that can effectively inhibit NLRP3 inflammasome production.
- Potential for the development of new medications for treating NLRP3 inflammasome-related diseases or disorders.
- Expanded treatment options for conditions associated with NLRP3 inflammasome activity.
Original Abstract Submitted
the invention relates to novel compounds for use as inhibitors of nlrp3 inflammasome production, wherein such compounds are as defined by compounds of formula (i) and wherein the integers r, rand rare defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with nlrp3 inflammasome activity.
